Portal de investigación
- Inicio
- Publicaciones
- QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) FLT3-ITD+ AML Patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perl, Alexander E.
- Erba, Harry P.
- Vrhovac, Radovan
- Patkowska, Elzbieta
- Kim, Hee-Je
- Zak, Pavel
- Wang, Po-Nan
- Rohrbach, Jaime E. Connolly
- Chang, Ken C. N.
- Liu, Li
- Kamel, Yasser Mostafa
- Imadalou, Karima
- Lesegretain, Arnaud
- Cortes, Jorge
- Sekeres, Mikkael A.
- Dombret, Herve
- Amadori, Sergio
- Wang, Jianxiang
- Schlenk, Richard F.
- Levis, Mark J.
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Perl,AE,Erba,HP,Montesinos,P,Vrhovac,R,Patkowska,E,Kim,H,Zak,P et al. QuANTUM-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication (<i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (ND) <i>FLT3</i>-ITD+ AML Patients. 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931:CIG MEDIA GROUP, LP. 2024 p.p. 298-298.